These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34185586)

  • 1. Trends in Endophthalmitis Associated With Intravitreal Injection of Anti-VEGF Agentsat a Tertiary Referral Center.
    Reyes-Capo DP; Yannuzzi NA; Smiddy WE; Flynn HW;
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):319-326. PubMed ID: 34185586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
    Gregori NZ; Flynn HW; Schwartz SG; Rosenfeld PJ; Vaziri K; Moshfeghi AA; Fortun JA; Kovach JL; Dubovy SR; Albini TA; Davis JL; Berrocal AM; Smiddy WE
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):643-8. PubMed ID: 26114845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC; Yu Y; VanderBeek BL
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
    Pancholy M; Storey PP; Levin HJ; Obeid A; Patel SN; Kuley B; Hsu J; Spirn MJ; Fineman M; Klufas MA; Gupta O; Ho AC; Garg SJ
    Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
    [No Abstract]   [Full Text] [Related]  

  • 7. Rates of Suspected Endophthalmitis Following Intravitreal Injections in Clinical Practices in the United States.
    Dhoot DS; Boucher N; Pitcher JD; Saroj N
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jun; 52(6):312-318. PubMed ID: 34185585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
    Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT
    Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
    Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center.
    Gonzalez-Gonzalez LA; Knickelbein JE; Doft BH; Balasubramani GK; Wisniewski S
    Int Ophthalmol; 2023 Mar; 43(3):867-876. PubMed ID: 36103102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates.
    VanderBeek BL; Bonaffini SG; Ma L
    Ophthalmology; 2015 Nov; 122(11):2311-2315.e1. PubMed ID: 26281823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
    Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
    Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength.
    Stem MS; Rao P; Lee IJ; Woodward MA; Faia LJ; Wolfe JD; Capone A; Covert D; Dass AB; Drenser KA; Garretson BR; Hassan TS; Margherio A; Oh KT; Raephaelian PV; Randhawa S; Sneed S; Trese MT; Yedavally S; Williams GA; Ruby AJ
    Ophthalmol Retina; 2019 Jan; 3(1):3-7. PubMed ID: 30929813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
    Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
    Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of patient face mask use on endophthalmitis after intravitreal anti-VEGF injections.
    Hébert M; You E; Hammamji K; Bourgault S; Caissie M; Tourville É; Dirani A
    Can J Ophthalmol; 2022 Dec; 57(6):364-369. PubMed ID: 34419421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endophthalmitis Associated With Intravitreal Injections of Anti-VEGF Agents at a Tertiary Referral Center: In-House and Referred Cases.
    Yannuzzi NA; Gregori NZ; Rosenfeld PJ; Relhan N; Patel NA; Si N; Miller D; Dubovy SR; Smiddy WE; Schwartz SG; Flynn HW
    Ophthalmic Surg Lasers Imaging Retina; 2018 May; 49(5):313-319. PubMed ID: 29772041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
    Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA
    Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
    Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
    Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of post-intravitreal anti-VEGF endophthalmitis at Thammasat University Hospital.
    Kanchanaranya N; Rojdamrongratana D; Piyasoonthorn P
    J Med Assoc Thai; 2015 May; 98(5):489-94. PubMed ID: 26058278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Immunosuppression and Risk of Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Patel SN; Storey PP; Kim JS; Obeid A; Pancholy M; Hsu J; Garg SJ
    Ophthalmic Surg Lasers Imaging Retina; 2021 Jul; 52(S1):S17-S22. PubMed ID: 34310237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.